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ABSTRACT 
Clozapine is an atypical antipsychotic used for the treatment of schizophrenia. The prescribed 
target daily doses may reach 900 mg. Literature studies report a connection between clozapine 
usage and thrombosis development. Our in vitro study aimed to provide insight into molecular 
bases of this observation, investigating clozapine binding to fibrinogen, the main plasma protein 
involved in hemostasis. Fibrinogen/clozapine interaction was confirmed by protein fluorescence 




. Direct interactions did not affect the 
structure of fibrinogen, nor fibrinogen melting temperature. Clozapine binding affected fibrin 
formation by reducing coagulation speed and thickness of fibrin fibers suggesting that in the 
presence of clozapine, fibrinogen may acquire thrombogenic characteristics. Although no 












synergistically with altered fibrin formation to modify fibrin clot, thus increasing the risk for 
development of thrombosis in patients on clozapine treatment. ORAC and HORAC assays 
showed that clozapine reduced free radical-induced oxidation of fibrinogen. All observed effects 
of clozapine on fibrinogen are dose-dependent, with the effect on fibrin formation being more 
pronounced. 
Keywords: fibrinogen; clozapine; binding; thrombosis; coagulation; hemostasis. 
1. INTRODUCTION 
Nearly half a century after launch, the first "atypical" antipsychotic drug clozapine (Fig. 
1A) is still the only medication licensed for treatment-resistant schizophrenia. Usually prescribed 
in the target doses of 300900 mg per day, clozapine is useful in the treatment of schizophrenia 
symptoms partially or fully resistant to treatment with other antipsychotic drugs, or accompanied 
by persistent suicidal or self-injurious behavior, by mechanisms that go beyond dopamine 
receptor (D2) blockade [1]. However, considerable effort should be made to balance superior 
clozapine antipsychotic efficacy with detection, monitoring, and reduction of drug side effects 
[2].  
Fibrinogen, one of the most abundant plasma proteins, is a sizeable fibrillar glycoprotein 
with (AαBβγ)2 structure and molecular mass of 340 kDa [3]. Also known as coagulation factor I, 
the primary biological function of fibrinogen is in the process of hemostasis. This protein is 
involved in both primary hemostasis, by its interaction with blood platelets and secondary 
hemostasis, by fibrin clot formation [4]. Fibrinogen interacts with proteins, ions, and small 
ligands, which all affect its functional properties [4-7].  
Literature reports suggest that patients who are on chronic clozapine treatment have an 












that may lead to this pathology is not yet known [1, 8-10]. One potential reason for the 
development of thrombosis may be the capability of clozapine to induce higher platelet activation 
and aggregation in the presence of agonists [11]. Venous thromboembolism may be a 
consequence of several risk factors for this pathology already present, such as metabolic 
syndrome and inactivity, besides the direct effect of clozapine on coagulation [12]. Sedation and 
body weight increase with the use of clozapine and can also lead to deep vein thrombosis [13]. It 
seems that the risk for the development of venous thromboembolism is higher in older patients 
and in women who are taking high doses of this drug [14-15]. Comparing concentrations of 
fibrinogen, plasminogen activator inhibitor-1 and anticoagulant factor antithrombin III, no 
significant differences were observed between patients receiving clozapine and their relatives 
[16].  
It is unknown on a molecular level how clozapine directly affects the development of 
thrombosis. In our study, we examined interactions of clozapine with fibrinogen and its influence 
on the functional aspect of fibrinogen. Fibrinogen is very susceptible to oxidation [17], and these 
modifications harm its function [18]. Since clozapine has undoubted antioxidant properties [19], 
in vitro potential to protect fibrinogen from free radical-induced oxidation was also investigated.  
2. MATERIALS AND METHODS 
2.1 Materials 
All chemicals used were purchased from Sigma (Germany). Fibrinogen was purified 
(Section 2.2) from a pool of human plasma obtained from 10 healthy adult donors, after 
receiving informed consent and INEP institutional review board approval. Human thrombin was 












provided by Remedica Ltd (Cyprus). A stock solution of the drug (4 mM) was prepared in 
DMSO. In all experiments performed, DMSO concentration was not higher than 1%.  
2.2 Isolation and quantification of human fibrinogen 
The double ammonium sulfate precipitation method was used for fibrinogen preparation 
[6]. A saturated solution of ammonium sulfate was added to a final concentration of 20%, and 
plasma was left at 4°C. After 30 min, plasma was centrifuged for 1 min at 10000 rpm at room 
temperature, and the obtained protein pellet was dissolved in 50 mM phosphate buffer, pH 7.2 
(this buffer was used in all experiments unless otherwise stated). Precipitation step was repeated 
as described, and after the dissolution of fibrinogen pellet in the same buffer, this solution was 
used as a protein source for all experiments. A product was homogeneous on SDS-PAGE. The 
concentration of the purified fibrinogen preparation was calculated using an extinction coefficient 
at 280 nm: E
1%
 = 15.1. 
2.3 Characterization of fibrinogen/clozapine binding by spectrofluorimetry 
For the determination of affinity constant and number of the binding site(s), the standard 
intrinsic protein fluorescence quenching method was used. The experiment was performed on 
FluoroMax®-4 spectrofluorometer (Horiba Scientific, Japan) at 37°C in triplicate. Fibrinogen (40 
nM) was titrated with an increasing concentration of clozapine (0.5 to 4 µM) and allowed to 
interact for one minute before each measurement. The excitation wavelength was 280 nm, and 
emission spectra were recorded in a range from 290 to 500 nm, with two accumulations, and slits 
set at 5 nm. The obtained average emission spectra (for each ligand bolus) were corrected by 
subtracting emission spectra originating from clozapine itself. Values of emission maxima at 345 
nm were corrected for inner filter effect using the following equation [20]:  












where Fc is the corrected fluorescence, F0 is the measured fluorescence, while Aex and 
Aem correspond to absorbances at excitation (280 nm) and emission (345 nm) clozapine peaks.  
The estimation of the binding (association) constant (Ka), and the number of binding sites 










where F0 and F are the emission signals of fibrinogen in the absence and the presence of 
clozapine, while [L] and [P] correspond to the total concentrations of the ligand and the protein.  
For determination of the type of quenching, Stern-Volmer (SV) plot was obtained using 
the following equation [20]: 
F0
F
= 1 + 𝑘𝑞𝜏𝑜[Q] = 1 + 𝐾𝑆𝑉[Q] 
where F0 and F are fluorescence intensities of fibrinogen at 345 nm without and with 
clozapine, kq is the bimolecular quenching rate constant, τo is the average lifetime of the protein 
without quencher (10
-8
 s), [Q] is the total quencher (clozapine) concentration, and KSV is the SV 
quenching constant. The obtained slope of the SV plot represents the SV quenching constant. 
Synchronous fluorescence spectra of fibrinogen/clozapine complex, using the same 
device and experimental setup, were obtained at two different scanning intervals: Δλ=15 nm, Tyr 
residues excitation with emission spectra recorded from 300 to 400 nm, and Δλ=60 nm, Trp 
residues excitation with emission spectra recorded from 275 to 350 nm, where Δλ = Δλem  Δλex. 
2.4 Analysis of fibrinogen/clozapine interaction using UV spectrometry 
UV spectrometric analysis of clozapine binding to fibrinogen was performed in triplicate 












range of 260360 nm for fibrinogen alone (5 µM), and in the presence of 10, 25, 50 and 100 µM 
clozapine. The obtained spectra were then corrected by subtracting the spectra for clozapine 
alone.  
2.5 Fourier-transformation infrared spectroscopy (FT-IR) analysis of fibrinogen/clozapine 
interaction 
FT-IR analysis was performed on IRAffinity-1 (Shimadzu, Japan) to investigate possible 
changes in fibrinogen secondary structure due to clozapine binding. Portions of 50 μL of samples 
(4 μM fibrinogen alone or in the presence of 8, 20, and 40 μM of cl zapine) were placed on ZnSe 
windows (32x2 mm; Thermo, Madison, USA) and dried using a stream of nitrogen. The 
measurements were performed in duplicate, using transmission mode with 100 scans per sample, 
while the resolution was 4 cm
-1
. Before further analyses, baselines of spectra were corrected 
using Spectragryph software [22]. Smoothing and Amide I peak deconvolution was performed 
using Origine Pro 8.6 software (OrigineLab, USA).  
2.6 Analysis of clozapine influence on fibrinogen melting temperature 
The influence of clozapine binding on fibrinogen temperature stability was determined on 
FluoroMax®-4 spectrofluorometer (Horiba Scientific, Japan) with the Peltier element. Thermal 
stability of fibrinogen alone (40 nM) or in the presence of clozapine (40 μM) was studied in the 
temperature range from 37 to 81°C by measuring fibrinogen intrinsic fluorescence reduction at its 
emission maximum (345 nm). The rate of temperature increase was 2°C/min, with the 
equilibration time set to 1 min, and both slits were 5 nm. Results are presented as sigmoidal 
function with the inflection point representing the melting temperature (Tm) of fibrinogen.  












Fibrinogen coagulation assay [23] was performed in tetraplicate at 37°C, with isolated 
fibrinogen at a final concentration of 0.34 μM, alone or in the presence of clozapine at final 
concentrations of 0.34 μM and 0.68 μM. The reaction mixture also contained a physiological 
concentration of CaCl2 (2.2 mM) and human thrombin (1 IU/mL). Immediately after thrombin 
addition, the cuvette was placed in the UV-1800 spectrophotometer (Shimadzu, Japan), and a rise 
in absorbance at 405 nm was continually followed for 8 min. The obtained results were analyzed 
according to the published procedure [23]. 
2.8 Analysis of clozapine influence on fibrin gel porosity 
The porosity of fibrin gel, obtained from 3 µM fibrinogen alone or in the presence of 3 
and 6 µM clozapine, was determined in tetraplicate by measuring Darcy constant, which is 
directly proportional to the porosity of the gel [24]. The reaction mixture for the formation of 
fibrin gel contained fibrinogen, clozapine, 2.2 mM CaCl2, and 1 IU/mL of thrombin. Immediately 
after thrombin addition, the reaction mixture was transferred to silicon tubes attached to 5 mL 
syringes and left to polymerase overnight in a humid chamber at room temperature. The next day, 
syringes were carefully mounted vertically on the holder and filled with phosphate buffer. Buffer 
was allowed to flow through fibrin gel for 30 min in pre-weighted microcentrifuge tubes, and the 
effluent was measured using an analytical balance. Darcy constant was calculated using the 
following equation:  
Ks = 
Q x L x η
t x A x ΔP
 
where Ks represents Darcy constant (cm
2
), Q is the volume of a liquid (mL) having 
viscosity η (P), flowing through a fibrin gel of the length L (cm) and cross-section A (cm
2
), in a 














2.9 ORAC antioxidant assay 
The ORAC assay [25] was performed in duplicate by measuring the reduction of intrinsic 
fluorescence of 100 nM fibrinogen, alone or in the presence of 3.4 and 6.8 µM clozapine. The 
reduction of protein fluorescence was achieved by incubating the samples with 52.5 mM AAPH 
(2,2'-azobis(2-amidinopropane) dihydrochloride), a free (dominantly peroxyl) radical inducer. 
Immediately after AAPH addition, samples were mixed and placed in a spectrofluorimeter. 
Emission maximum of fibrinogen at 345 nm was monitored (FluoroMax®-4, Horiba Scientific, 
Japan) upon excitation at 280 nm for 25 min at 37°C with slits of 5 nm. Protective effect (PE) of 
clozapine, expressed in arbitrary units (A.U.), was calculated using the equation [26]: 
PE (A.U.) [x 10
6
] = AUCFIB+CLZ  AUCFIB 
where AUCFIB+CLZ represents the area under the curve obtained for fibrinogen/clozapine 
mixture and AUCFIB represents the area under the curve obtained for fibrinogen alone. 
2.10 HORAC antioxidant assay 
In the HORAC assay, the reduction of fluorescence of 100 nM fibrinogen, alone or in the 
presence of 6.8 and 13.6 µM clozapine, was achieved by incubating samples with the substances 
[25] inducing hydroxyl radical production (31 mM H2O2 and 260 µM CoF2 x 4H2O/ 460 µM 
picolinic acid). Immediately after the addition of all components, mixtures were placed in 
FluoroMax®-4 spectrofluorimeter (Horiba Scientific, Japan). The further procedure and 
quantification of the protective drug effect against free radical-induced protein oxidation were 
identical to that described in Section 2.9. 
3. RESULTS AND DISCUSSION 












The protein fluorescence quenching method is widely used for the characterization of 
small ligand binding. The presence of clozapine efficiently quenches the intrinsic fluorescence of 
fibrinogen when protein is excited at 280 nm (Fig. 1B). Increasing concentrations of clozapine do 
not cause either red or blue shift of the emission maximum of the protein, suggesting that the 
environment around Trp and Tyr amino acid residues is not altered as a consequence of binding. 
From the equation obtained from the double log plot (Fig. 1C), affinity constant was calculated 




, with the number of binding sites of 1.2 ± 0.08.  
Of all plasma proteins, so far, it was known that clozapine specifically binds only to 
human serum albumin (HSA). HSA is a transport protein with multiple ligand binding sites, 
primarily for acidic and neutral drugs [27]. Indeed, about 95% of clozapine in blood was found to 
be bound for HSA [28]. What is interesting is that the estimated affinity constant of fibrinogen 
for clozapine is an order of magnitude higher compared to HSA/clozapine complex [29]. The 
referent level of fibrinogen in plasma (24 g/L; i.e., 5.9μ) is much lower than for albumin 
(3550 g/L; i.e., 0.53m), as well as its half-life (4 vs. 20 days, respectively). The target 
clozapine plasma levels for the vast majority of patients are 350450 μg/L [30], i.e., 1.1μ. 
Therefore, it seems that preferential clozapine binding to fibrinogen (as assessed by Ka) over 
HSA will not significantly affect the distribution of the free (active) drug in the circulation and 
thus its pharmacological properties. However, in the situations when the concentration of 
fibrinogen is increased (for example due to inflammation), or the concentration of albumin 
decreased (for example due to impaired kidney function) or if the structure of albumin is 
modified (e.g., glycated), the equilibrium between two proteins and, thus, clozapine binding may 






















Since the bimolecular quenching rate constant is about two orders of magnitude higher than the 






), the obtained results suggest that in the presence of 
clozapine static quenching of fibrinogen takes place [20]. Based on synchronous fluorescence 
data (Figs. 1E and 1F), it follows that both Trp and Tyr residues of fibrinogen notably contribute 
to the quenching of signal induced by clozapine binding. While HSA has only one, human 
fibrinogen contains as many as 41 Trp residues [32], which jointly with 67 Tyr residues imply 
that binding of clozapine occurs in an area with both of these amino acids in proximity. 
Our results show for the first time that fibrinogen s ecifically binds clozapine under 
(partially) simulated pathophysiological conditions. 
3.2 Examination of clozapine binding effects on fibrinogen structure and stability 
Although generally very small, alterations in the absorption spectra are beneficial for the 
detection of conformational changes of a protein and ligand binding. UV spectral analysis of 
clozapine binding to fibrinogen (Section 2.4) indicates no changes in protein structure (Fig. 2A). 
Since differences in the absorbance can result as a consequence of environment alterations close 
to aromatic amino acid side chains [33], it seems that this was not the case here, confirming the 
results obtained from the fluorescence quenching study. 
Fourier-transform infrared spectroscopy is one of the most versatile analytical tools in life 
sciences. FT-IR analysis was performed in our work (Section 2.5) to examine if changes in the 
secondary structure of fibrinogen occur upon clozapine binding. The deconvolution of Amide I 
region from the obtained spectra resulted in 5 peaks (Fig. 2B), revealing a secondary structure 












which is following the published FT-IR fibrinogen data [34]. Differences in the proportion of the 
secondary structure components are insignificant in the presence of even a high concentration of 
clozapine (Fig. 2C).  
Another confirmation that the binding of clozapine has no significant effect on the 
structure and stability of native fibrinogen came from the results of thermal stability analysis 
(Section 2.6). As can be seen from the obtained graphs (Fig. 2D), the melting temperature 
(inflection point on graphs) of fibrinogen is only slightly (0.8°C) higher in the presence of 
clozapine.  
Summing-up all experimental data, it can be said that the formation of complexes 
between clozapine and fibrinogen has a negligible effect on protein structure and thermal 
stability. These findings are not surprising. Fibrinogen is a large, fibrillar type of protein, whose 
structure/stability is not expected to change easily by small ligand binding, as was previously 
shown in the case of bilirubin [6]. On the other hand, clozapine binding induces a small but 
significant reduction of the α-helix content in HSA [29]. 
3.3 Examination of clozapine binding effects on fibrinogen function 
Fibrinogen is involved in both primary and secondary hemostasis, playing an essential 
role in platelet aggregation and the formation of a fibrin network. While some direct/indirect 
mechanisms that may lead to thrombotic complications in patients on clozapine therapy are 
known [11-13], exact mechanisms at the molecular level are not elucidated. Therefore, we 
examined differences in the functional properties between fibrinogen and fibrinogen/clozapine 
complexes (Sections 2.7/2.8). 
In the presence of an increased clozapine concentration, fibrinogen formed fibrin clot at 












maximal absorbance at 405 nm at the end of fibrin formation) (Fig. 3A). These functional 
characteristics of fibrinogen are similar to those found when fibrinogen was incubated with high 
(10 mM) concentrations of glucose [35], and for fibrinogen isolated from patients with post-
acute myocardial infarction [36], where the protein was extensively post-translationally modified. 
While fibrin clot with thinner fibers is usually more compact and less porous, this was not the 
case in our study: similar porosity was obtained with native fibrin and fibrin in the presence of all 
tested concentrations of clozapine (Fig. 3B).  
Many factors in the blood affect the outcome of fibrin clot formation and its 
characteristics [37]. Further, some pathologies are characterized by fibrin clots that have thicker 
fibers compared to healthy controls, but these clots also have lower porosity [38]. Fibrin 
formation is a very complex process involving many factors. Altered fibrin formation as a 
consequence of clozapine binding may not be sufficient enough to enable the detection of 
significant alterations in fibrin porosity and to lead to thrombotic behavior directly. However, the 
detected impact of clozapine on fibrin formation may act synergistically with other factors and 
contribute to the impairment of the coagulation process, which may progress to the development 
of thrombosis. Many studies reported on the reduced porosity of fibrin clots that also have thinner 
fibrin fibers [39-42]. It was also reported that patients with schizophrenia are in the 
hypercoagulable and hypofibrinolytic state, both of which may aid in their increased risk of 
venous thromboembolism [43]. Further controlled studies involving whole plasma from patients 
on long-term clozapine therapy are needed to determine the extent to which coagulation 
characteristics of fibrinogen are altered.  
The results of our study unambiguously document a clozapine dose-dependent influence 












3.4 Examination of clozapine binding effects on fibrinogen stability against oxidation 
Fibrinogen is one of the plasma proteins most susceptible to oxidative modifications. An 
important factor that usually leads to reduced fibrin porosity is precisely the oxidation of 
fibrinogen. This modification creates new hydrophobic regions in fibrin clots that are less 
permeable for plasmin, the main protein involved in fibrinolysis [44]. For these reasons, small 
molecules with antioxidant properties that bind fibrinogen may have a beneficial effect on the 
coagulation process by protecting protein from free radical-induced oxidation. 
 Results obtained in ORAC and HORAC tests, where protein, not fluorescein was a target 
of free radical-induced oxidation (Sections 2.9/2.10), suggest that clozapine is capable of 
protecting fibrinogen from oxidation, in a dose-dependent manner (Figs. 4A and 4B). Calculated 
protective effect (corresponding to the difference in areas under the curves in the presence and 
absence of drug, expressed in arbitrary units) in ORAC assay was 71 in the presence of 3.4 μM 
clozapine and even 128 in the presence of 6.8 μM clozapine. The same trend was evident in the 
HORAC assay as well, where the protective effect was 102 in the case of 6.8 μM clozapine and 
373 in the case of 13.2 μM clozapine. The chemical structure-related antioxidant capacity of 
clozapine points to its possible neuroprotective potential on the top of its complex antipsychotic 
mechanism of action [45]. Our results showed that clozapine binding may reduce the oxidation of 
fibrinogen. Based on the molar ratios of fibrinogen and clozapine used, our in vitro experimental 
results suggest that clozapine has a more pronounced effect on fibrin formation than on oxidative 
protection of fibrinogen.  
4. CONCLUSION 
Clozapine interacts with isolated fibrinogen, under simulated pathophysiological 












transporter of drugs. Although this binding has a negligible effect on the structure and thermal 
stability of fibrinogen, it influences fibrin formation and may contribute to its observed 
thrombogenic characteristics in patients on chronic clozapine treatment. On the other hand, 
clozapine can reduce harmful (free radical-induced) oxidation of fibrinogen. Both detected 
effects of clozapine are dose-dependent, with the effect on fibrin formation being more 
pronounced.  
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FIGURE CAPTIONS 
Fig. 1. The quenching of fibrinogen fluorescence by clozapine. A) Chemical structure of 
clozapine (8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine). B) 
Representative emission spectra (excitation at 280 nm) of fibrinogen (40 nM) in the presence of 
increasing concentrations of clozapine (0–4 μM). C) Double log plot used for the calculation of 
the binding parameters: affinity constant and number of binding sites; Error bars represent the 
standard deviation (n=3). D) Stern-Volmer (SV) plot used for the calculation of SV quenching 
constant (KSV); Error bars represent the standard deviation (n=3). Representative synchronous 
fluorescence spectra of fibrinogen (40 nM) with E) Δλ=60 nm (Trp) and with F) Δλ=15 nm (Tyr) 












Fig. 2. The influence of clozapine binding on fibrinogen structure and stability. A) UV spectra of 
fibrinogen (5 μM) in the presence of increased concentrations of clozapine (0–100 μM). FT-IR 
absorption spectra (deconvolution results) of B) fibrinogen alone (4 μM) and C) in the presence 
of 40 μM clozapine. D) Thermal stability of fibrinogen alone (40 nM) and in the presence of 
clozapine (40 μM). 
Fig. 3. Effects of fibrinogen/clozapine binding on protein function. A) Fibrin formation from 
isolated fibrinogen (0.34 μM) in the presence of an increasing clozapine concentration (0, 0.34, 
and 0.68 μM). B) The porosity of fibrin gel formed from the isolated fibrinogen (3 μM) in the 
presence of an increasing clozapine concentration (0, 3, and 6 μM). 
Fig. 4. Effects of fibrinogen/clozapine binding on the free radical-induced protein oxidation. 
Fibrinogen (0.1 μM) fluorescence decay in A) ORAC and B) HORAC antioxidant assays in the 
presence of increasing concentrations of clozapine (0, 3.4, and 6.8 μM in ORAC and 0, 6.8, and 
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Clozapine binding has a negligible influence of fibrinogen structure and stability. 
Clozapine binding unfavorably changes fibrinogen functional properties. 
Clozapine binding reduces free-radical induced fibrinogen oxidation. 
The effects of clozapine binding to fibrinogen are dose-dependent. 
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